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were estimated by expert opinion. If two or more studies esti-
mated utility for a similar disease state then a meta-analysis was
carried out to pool the variance weighted mean estimates.
RESULTS: Twenty-eight studies measured utilities of liver dis-
eases or disease states. Only nine of these studies were eligible
for meta-analysis for four health states in chronic liver disease
patients (compensated cirrhosis, decompensated cirrhosis, pre-
liver transplant and post-liver transplant) and three in Hepatitis
C patients (compensated cirrhosis, decompensated cirrhosis and
post-liver transplant). The pooled mean estimates in chronic liver
disease and hepatitis C patients with compensated cirrhosis were
0.87 (95% CI 0.62 to 1.12) and 0.83 (95% CI 0.68 to 0.99)
respectively. For decompensated cirrhosis they were 0.68 (95%
CI 0.40 to 0.95) and 0.73 (95% CI 0.50 to 0.97). For post-liver
transplant, the estimates were 0.70 (95% CI 0.40 to 1.01) and
0.76 (95% CI 0.52 to 1.01) respectively. Pre-liver transplant
patients with chronic liver disease had a utility estimate of 0.57
(95% CI 0.28 to 0.87). CONCLUSIONS: We have estimated
summaries of patient utilities for the major states of chronic liver
disease and hepatitis C, and created a valuable liver disease-
based utility resource for researchers and policy makers.
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OBJECTIVE: Compare maximum acceptable risk (MAR) of
treatment-related serious adverse events (SAE) between adult
Crohn’s disease (CD) patients and parents of children with CD.
Information on beneﬁt-risk tradeoffs may aid clinicians and reg-
ulatory agencies in their decision-making. METHODS: An on-
line panel of adult CD patients and parents of children with CD
completed a series of choice-format conjoint tradeoff tasks. The
treatment attributes included daily symptom severity and activ-
ity limitations, the potential for serious disease complications,
the time between ﬂare-ups, oral steroid use, and varying levels
of three SAE mortality risks: serious infection, progressive mul-
tifocal leukoencephalopathy (PML) and lymphoma. The annual
MAR was calculated for 15 SAE-clinical beneﬁt combinations (3
SAEs X 5 levels of clinical improvement from a severe or mod-
erate CD state). RESULTS: A total of 357 adult patients and 105
parents completed the survey. Improvements in daily symptom
severity were the most important factor in treatment preferences.
Higher MAR (greater risk acceptance) was observed for trade-
off tasks involving higher levels of clinical beneﬁt. Compared to
adult patients, parents were willing to accept a greater SAE risk
for alleviation of severe CD symptoms (for 7 of 9 SAE vs. clin-
ical beneﬁt combinations), but were less willing to accept SAE
risk for improvement of moderate CD symptoms (for 6 of 6 com-
binations). CONCLUSIONS: Medical interventions carry risks
of adverse outcomes that must be evaluated against their clini-
cal beneﬁts. Adult patients and parents of children with CD indi-
cated they are willing to accept deﬁned mortality risks in
exchange for clinical efﬁcacy. While parents were more willing
to accept higher SAE risks for improvement of severe CD symp-
toms, patients were willing to accept higher risks for improve-
ment of moderate CD symptoms.
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OBJECTIVES: GERD is a frequent condition among the general
population, which is not often properly diagnosed or treated.
The study aimed to depict the prevalence of GERD within a
primary care setting, assess symptoms severity and frequency in
GERD patients, and to examine the association between GERD
and aspirin/NSAIDs use. METHODS: A total of 2878 individu-
als (M/F: 1411/1467, mean age 55, 19 ± 14,5 years, BMI 26, 7
± 3, 9 Kg/m2) visiting 300 Primary Care Practitioners (PCP)
between November-December 2005 were included. Demo-
graphic and medical history data including aspirin/NSAID use,
the presence and severity-frequency of GERD and dyspepsia
symptoms were recorded, using a structured questionnaire.
GERD (heartburn, regurgitation) and dyspepsia (epigastric pain,
early satiety, postprandial fullness) diagnoses were based on
widely accepted epidemiological criteria. RESULTS: The main
reasons for patients visiting PCPs were prescription renewal
(32.9%) and consultation for upper GI symptoms (28.6%).
GERD symptoms were reported by 57.4% and dyspepsia by
67.6% of the 2878 patients during the last week before visiting
their PCP. Among patients with upper GI symptoms, GERD or
dyspepsia was reported almost equally as predominant symptom
by 34.2% and 35.6% of patients respectively, while another
4.9% reported symptoms of both diagnoses as predominant.
GERD symptoms were mild in 33%, moderate in 40% and
severe in 12% of the patients, while present for 2 days/week in
29%, 3–5 days/week in 39% and 6–7 days/week in 17% of
cases. GERD and/or dyspepsia symptoms were reported by
81.7% of users and as opposed to 62.5% of non-aspirin/NSAID
users during the last two weeks before visiting their PCP (P =
0.043). CONCLUSIONS: In patients who use primary care
health resources, GERD symptoms are highly prevalent (57%),
being present for at least 2 days/week in 85% and of moder-
ate/severe intensity in more than 50% of symptomatic patients.
Aspirin/NSAID use substantially increases prevalence of GERD
and dyspepsia symptoms.
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The validity of the work productivity and activity impairment
(WPAI) questionnaire in the measurement of health-related pro-
ductivity was demonstrated in gastroesophageal reﬂux disease
and irritable bowel syndrome. The Crohn’s disease (CD) speciﬁc
WPAI (WPAI:CD) was administered in two large clinical trials
PRECiSE 1 and PRECiSE 2 that demonstrated the efﬁcacy and
tolerability of Certolizumab Pegol subcutaneous once monthly,
vs. placebo, in patients with moderate to severe CD. OBJEC-
TIVES: The objective was to compare the WPAI : CD scores of
patients categorized by baseline disease severity and health-
related quality of life (HRQoL) level, with the a priori assump-
tion that more severe health conditions are associated with
higher impairments in work productivity and daily activities.
METHODS: The 1330 randomized patients were divided into
“best” and “worst” subgroups determined by the CD Activity
